Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $13.34 in the prior trading day, 10x Genomics Inc (NASDAQ: TXG) closed at $13.57, up 1.72%. In other words, the price has increased by $1.72 from its previous closing price. On the day, 1.71 million shares were traded. TXG stock price reached its highest trading level at $13.5801 during the session, while it also had its lowest trading level at $12.97.
Ratios:
Our goal is to gain a better understanding of TXG by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.70. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.84. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Downgraded its rating to Market Perform and sets its target price to $12 from $25 previously.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.
Jefferies Upgraded its Hold to Buy on July 22, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Saxonov Serge sold 9,348 shares for $13.79 per share. The transaction valued at 128,881 led to the insider holds 945,892 shares of the business.
Taich Adam sold 22,315 shares of TXG for $307,657 on Aug 22 ’25. The Chief Financial Officer now owns 309,273 shares after completing the transaction at $13.79 per share. On Aug 22 ’25, another insider, Hindson Benjamin J., who serves as the insider of the company, sold 7,486 shares for $13.79 each. As a result, the insider received 103,209 and left with 440,888 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 1659461632 and an Enterprise Value of 1328816896. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.62 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 2.062 whereas that against EBITDA is -11.987.
Stock Price History:
The Beta on a monthly basis for TXG is 2.09, which has changed by -0.3700093 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $24.38, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 4.14%, while the 200-Day Moving Average is calculated to be 13.17%.
Shares Statistics:
The stock has traded on average 3.54M shares per day over the past 3-months and 2081690 shares per day over the last 10 days, according to various share statistics. A total of 114.36M shares are outstanding, with a floating share count of 110.42M. Insiders hold about 11.30% of the company’s shares, while institutions hold 98.39% stake in the company. Shares short for TXG as of 1755216000 were 13643549 with a Short Ratio of 3.85, compared to 1752537600 on 14263062. Therefore, it implies a Short% of Shares Outstanding of 13643549 and a Short% of Float of 17.59.
Earnings Estimates
The market rating of 10x Genomics Inc (TXG) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.01 and low estimates of -$0.07.
Analysts are recommending an EPS of between $0.39 and -$0.22 for the fiscal current year, implying an average EPS of $0.09. EPS for the following year is -$0.17, with 2.0 analysts recommending between -$0.04 and -$0.29.
Revenue Estimates
14 analysts predict $142.64M in revenue for the current quarter. It ranges from a high estimate of $145.6M to a low estimate of $139.56M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $151.65MFor the next quarter, 14 analysts are estimating revenue of $150.84M. There is a high estimate of $157.8M for the next quarter, whereas the lowest estimate is $146M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $625.3M, while the lowest revenue estimate was $573.71M, resulting in an average revenue estimate of $615.81M. In the same quarter a year ago, actual revenue was $610.78MBased on 15 analysts’ estimates, the company’s revenue will be $609.08M in the next fiscal year. The high estimate is $626.4M and the low estimate is $592.9M.
